Select publications
Cassidy J et al. First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Proc ESMO 2006;Abstract LBA3.
Chung KY, Kelsen D. Adjuvant therapy for Stage II colorectal cancer: Who and with
what? Curr Treat Options Gastroenterol 2006;9(3):272-80. Abstract
Diep CB et al. Genetic tumor markers with prognostic impact in Dukes’ stages B and C colorectal cancer patients. J Clin Oncol 2003;21(5):820-9. Abstract
Lang I et al. Cetuximab with irinotecan in first-line treatment of epidermal growth
factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC). Preliminary safety results (CRYSTAL). Proc ASCO 2006;Abstract 3555.
Locker GY et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24(33):5313-27. Abstract
Sarli L et al. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q. Dis Colon Rectum 2004;47(9):1467-82. Abstract
Van Cutsem E et al. Cetuximab dose-escalation study in patients with metastatic
colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic and efficacy data of a randomized study. Gastrointestinal Cancers Symposium 2007;Abstract 237.
Venook A et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/
LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. Proc ASCO 2006;Abstract 3509.
